NDC 71335-1066 – Celecoxib
Celecoxib 200 mg/1 · Capsule · Oral
Product NDC71335-1066
Product details
- Brand name
- Celecoxib
- Generic name
- Celecoxib
- Labeler
- Bryant Ranch Prepack
- Dosage form
- Capsule
- Route
- Oral
- Marketing category
- ANDA · ANDA204776
- Marketed since
- June 1, 2018
- Listing expires
- December 31, 2026
- Pharmacologic class
- Nonsteroidal Anti-inflammatory Drug
Active ingredients
- Celecoxib 200 mg/1
Package NDC codes (10)
| Package NDC | Description | Since |
|---|---|---|
| 71335-1066-0 | 15 CAPSULE in 1 BOTTLE (71335-1066-0) | Sep 9, 2021 |
| 71335-1066-1 | 30 CAPSULE in 1 BOTTLE (71335-1066-1) | Feb 8, 2019 |
| 71335-1066-2 | 60 CAPSULE in 1 BOTTLE (71335-1066-2) | May 24, 2021 |
| 71335-1066-3 | 90 CAPSULE in 1 BOTTLE (71335-1066-3) | Apr 17, 2019 |
| 71335-1066-4 | 14 CAPSULE in 1 BOTTLE (71335-1066-4) | Mar 20, 2020 |
| 71335-1066-5 | 20 CAPSULE in 1 BOTTLE (71335-1066-5) | May 6, 2022 |
| 71335-1066-6 | 10 CAPSULE in 1 BOTTLE (71335-1066-6) | May 1, 2019 |
| 71335-1066-7 | 180 CAPSULE in 1 BOTTLE (71335-1066-7) | Jan 29, 2025 |
| 71335-1066-8 | 28 CAPSULE in 1 BOTTLE (71335-1066-8) | Jun 21, 2021 |
| 71335-1066-9 | 56 CAPSULE in 1 BOTTLE (71335-1066-9) | Jan 29, 2025 |
Other Celecoxib products
- 50090-6758 Celecoxib 200 mg/1 · Capsule · A-S Medication Solutions
- 50090-5178 Celecoxib 200 mg/1 · Capsule · A-S Medication Solutions
- 50090-6577 Celecoxib 200 mg/1 · Capsule · A-S Medication Solutions
- 50090-5638 Celecoxib 200 mg/1 · Capsule · A-S Medication Solutions
- 50090-7072 Celecoxib 200 mg/1 · Capsule · A-S Medication Solutions
- 50090-6759 Celecoxib 200 mg/1 · Capsule · A-S Medication Solutions
- 50090-8036 Celecoxib 100 mg/1 · Capsule · A-S Medication Solutions
- 50090-8031 Celecoxib 100 mg/1 · Capsule · A-S Medication Solutions
- 50090-4789 Celecoxib 200 mg/1 · Capsule · A-S Medication Solutions
- 50090-6380 Celecoxib 100 mg/1 · Capsule · A-S Medication Solutions
- 0591-3983 Celecoxib 100 mg/1 · Capsule · Actavis Pharma, Inc.
- 0591-3984 Celecoxib 200 mg/1 · Capsule · Actavis Pharma, Inc.